Back to Search
Start Over
Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
- Source :
- Cardiology Discovery, Vol 1, Iss 1, Pp 37-43 (2021)
- Publication Year :
- 2021
- Publisher :
- Wolters Kluwer Health/LWW, 2021.
-
Abstract
- Abstract. Objective:. Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM). Methods:. This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5–7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization. Results:. Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes
- Subjects :
- Diseases of the circulatory (Cardiovascular) system
RC666-701
Subjects
Details
- Language :
- English
- ISSN :
- 26938499 and 00000000
- Volume :
- 1
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Cardiology Discovery
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.373a780aa3a4b9d8cc42c302dfe6788
- Document Type :
- article
- Full Text :
- https://doi.org/10.1097/CD9.0000000000000014